Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers
NCT06878170Phase 1Completed
- Sponsor
- Rock BioMedical, Inc.
- Start
- Sep 2024
- Primary completion
- Jan 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RBM-001 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Rock BioMedical, Inc. Primary endpoints: Solicited local and general adverse events at Day 29, Unsolicited adverse events at Day 43 and 3 more. Started Sep 2024; status: completed.
02
Drugs
RBM-001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06878170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06878170.